Liraglutide (Saxenda) NICE Technology Appraisal TA664 recommends liraglutide as an option for managing overweight and obesity in adults with a BMI of 35 kg/m or more (or 3034.9 kg/m in certain circumstances) alongside at least one weight-related comorbidity, within a specialist weight management service
Such an approach would, for instance, employ an osteoinductive peptide coupled by a peptide promoting the osteogenic or chondrogenic response
Hundreds of distinct mycotoxins have been identified
It supports the activity of fibroblasts and endothelial cells, key players in the repair of damaged tissues, enabling more efficient and effective healing ( 1, 3 )
Screen of FDA-approved drug library reveals compounds that protect hair cells from aminoglycosides and cisplatin
Results observed in one study or experimental model should not be expected in every research setting